Breakout Stock with Stellar Q2 FY25 Results, Profit Surged by 350 Per cent; LIC-Backed Stock Rallies Over 15 Per cent – Do You Own It?

The company’s shares have rallied and delivered a multibagger return of over 170 per cent in just 1 year.

This Small-Cap company is a part of the Piramal Group, operates across three key segments: Contract Development and Manufacturing Organizations (CDMO), Complex Hospital Generics (Critical Care), and Consumer Healthcare (OTC products). The company first entered the pharmaceutical industry in 1988 through the acquisition of Nicholas Laboratories and expanded significantly through a combination of mergers, acquisitions, and organic growth.

Piramal Pharma Ltd’s shares have rallied around 20 per cent with a significant surge in volumes on Thursday. Additionally, the shares have broken out from a 44-day consolidation period and achieved both a trendline breakout and a new 52-week high, as well as an all-time high price. Today, the stock closed the trading day at its all-time high. Over the past year, the company’s shares have delivered a multibagger return of over 170 per cent.

Q2 FY25 Financial Performance

As per the Quarterly Results, in the first quarter of FY25, Piramal Pharma Ltd recorded a revenue of Rs 2242 crore compared to Rs 1911 crore. The operating profit for the period stood at Rs 342 crore with a margin of 15 per cent. The net profit for Q1 FY25 was Rs 23 crore compared to Rs 5 crore representing a gain of around 360 per cent YoY. Looking at the annual performance, the company generated a revenue of Rs 8171 crore in FY24, compared to Rs 7082 crore in FY23. The operating profit for FY24 was Rs 1197 crore, with a net profit of Rs 18 crore compared to a loss of Rs 186 crore.

Disclaimer: The article is for informational purposes only and not investment advice.